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ABSTRACT 
Introduction: The solute carrier organic anion transporting polypeptide 1A2 (OATP1A2, 
SLCO1A2) is implicated in the cellular influx of a number of drugs.  
Methods and Materials: We identified five novel single nucleotide polymorphisms (SNPs) 
in coding exons of the SLCO1A2 gene in a cohort of subjects: G550A, G553A, G673A, 
A775C and G862A, that encoded the OATP1A2 variants E184K, D185N, V255I, T259P 
and D288N, respectively. The function and expression of these variant transporters 
were assessed in the HEK-293 cells.  
Results and Discussion: We found that the novel variants, E184K, D185N, T259P and 
D288N, were associated with impaired estrone-3-sulfate, imatinib and methotrexate 
transport (~20%-50% of wild type control); function was retained by OATP1A2-V255I. 
From biotinylation assays the decreased function of these variants was due, at least in 
part, to impaired plasma membrane expression. The four loss-of-function variants were 
studied further using mutagenesis to produce variants that encode residues with 
different charges or steric properties. From immunoblotting, the replacement of 
negatively charged residues at amino acid positions 184 and 185 impaired membrane 
expression, while either a positive or negative charge at residue 288 supported the 
correct membrane targeting of OATP1A2.  Replacement of T259 with bulky residues 
disrupted transporter stability. From molecular models E184, D185 and D288 were 
located near several charged residues such that intramolecular ionic interactions may 
stabilize the transporter structure.  
Conclusion: Individuals who carry these novel SNPs in the SLCO1A2 gene may be at 
risk from impaired efficacy or enhanced toxicity during treatment with drugs that are 
substrates for OATP1A2.  
Keywords: Organic anion transporting polypeptide 1A2; SLCO1A2; polymorphisms; 
transporter variants. 
 
 
Introduction 
Organic anion transporting polypeptides (OATPs), encoded by the SLCO gene family, 
are expressed in epithelial cells from multiple tissues and mediate the cellular influx of 
organic anions, including a number of clinically important drugs. Because OATPs 
influence drug absorption, distribution and elimination, factors that impair function may 
influence therapeutic efficacy and toxicity (1-3). An important source of impaired 
function is pharmacogenetic variation caused by single nucleotide polymorphisms 
(SNPs) that alter the primary amino acid sequence of the encoded transporter. Thus, 
naturally occurring genetic variants in SLCO transporter genes may contribute to 
variable patient responses to certain drugs. 
OATP1A2 (SLCO1A2) is an important member of the OATP transporter family that is 
expressed at the apical surface of the intestinal epithelium and renal tubules, in brain 
capillary endothelium and in biliary cholangiocytes (3-9). OATP1A2 participates in the 
intestinal absorption of drug substrates (3, 4), facilitates the tubular reabsorption of 
xenobiotics from urine as well as their secretion in bile (5) and may also influence 
uptake of drugs into brain (7). Endogenous substrates of OATP1A2 include bile acids, 
steroid and thyroid hormones, and their conjugates. Important drug substrates include 
imatinib, fexofenadine, methotrexate, HIV protease inhibitors, HMG-CoA reductase 
inhibitors, and certain peptides (3, 7, 10-14). Several studies have shown that the 
cellular uptake and pharmacokinetic behavior of some drugs may be impaired in the 
case of certain OATP1A2 variants (3, 9). 
A number of studies have characterized the impact of pharmacogenetic variation in SLC 
transporters and their impact on transport function. Several naturally occurring SNPs in 
genes encoding OATPs have been identified that affect function (3, 15-21). Limited 
information is available on how polymorphisms alter the function of OATP1A2 (3, 9). 
Given the substrate specificity and expression of OATP1A2 in organs of importance to 
drug disposition and response, genetic variations in SLCO1A2 may have significant 
pharmacologic and toxicological consequences. In the present study the coding exons 
in the SLCO1A2 gene were sequenced in genomic DNA from a previously described 
cohort of subjects (22) and five novel variants were identified. The impact of the newly 
id4entified SNPs on OATP1A2 transporter function and expression was assessed in 
cells. Particular amino acid residues in putative intracellular loops that are subject to 
pharmacogenetic variation were identified that have critical roles in the stability and 
membrane expression of the transporter. Together these findings identify new roles in 
intracellular amino acid residues that direct OATP1A2 to the plasma membrane. 
 
Materials and Methods 
Materials 
[3H] Estrone sulfate (E3S; specific activity 57.3 Ci/mmol) was purchased from 
PerkinElmer (Melbourne, VIC, Australia), [3H] methotrexate (MTX; specific activity 
15.7Ci/mmol) was purchased from BioScientific (Kirrawee, NSW, Australia) and [14C]-
imatinib (specific activity 51 mCi/mmol) was generously provided by Novartis (North 
Ryde, NSW, Australia). Culture media was obtained from Thermo Scientific (Lidcombe, 
NSW, Australia). Chloroquine, leupeptin, pepstatin and lactacystin were purchased from 
Sapphire Biosciences (Redfern, NSW, Australia).  Unless otherwise stated all other 
chemicals and biochemicals were purchased from Sigma-Aldrich (Castle Hill, NSW, 
Australia). 
Novel	  pharmacogenomics	  variants	  of	  SLCO1A2	  and	  expressing	  in	  HEK-­‐293	  cells	  
The	  present	  study	  was	  approved	  by	  Institutional	  ethics	  committees	  of	  the	  Western	  Sydney	  Area	  Health	  
Service	   and	   the	   University	   of	   Sydney,	   and	   conformed	   to	   the	   Declaration	   of	   Helsinki.	   (22).	   DNA	   was	  
isolated	   from	  whole	   blood	   taken	   from	  22	  human	   subjects	  who	  had	  previously	   received	   imatinib	   (22).	  
Resequencing	  of	  all	  coding	  exons	  in	  the	  SLCO1A2	  gene	  was	  undertaken	  using	  KAPA HiFi PCR Kits 
(Geneworks, Hindmarsh SA, Australia). The primers used in amplification of the SLCO1A2	  
gene are shown in Table 1. Amplified	  DNA	  was	  purified	  on	  Wizard	  SV	  Gel	  and	  PCR	  clean	  up	  system	  
(Promega,	  Alexandria,	  NSW,	  Australia)	  and	  subjected	  to	  bidirectional	  sequencing	  (Ramaciotti	  Centre	  for	  
Gene	  Function	  Analysis,	  Randwick,	  NSW,	  Australia).	   
The SLCO1A2 cDNA was purchased from GeneCopoeia (Cat. NO: GC-Q0577). 
Specific nucleotide changes were generated using Pfu DNA polymerase (Promega, 
Alexandria, NSW, Australia) following the manufacturer's instructions. All sequences 
were confirmed by the dideoxy chain termination method (Ramaciotti	   Centre	   for	   Gene	  
Function	   Analysis). HEK-293 cells were maintained at 37°C and 5% CO2 in Dulbecco's 
modified Eagle's medium supplemented with 10% fetal calf serum. Cells were 
transfected with plasmid DNA using Lipofectamine 2000 Reagent (Invitrogen, Mount 
Waverley, VIC, Australia) following the manufacturer's instructions. Twenty-four h after 
transfection substrate uptake activities were measured. 
Transport Studies 
Cellular uptake of [3H]-E3S (final concentration 0.3 µM, 67 nCi/well) in HEK-293 cells 
was conducted at 25oC as described previously (11, 23). Uptake was initiated in 
phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.4 mM 
KH2PO4, pH 7.4) containing 1 mM CaCl2, and 1 mM MgCl2, and was terminated by 
rapidly washing the cells in buffer at 4oC. Preliminary experiments indicated that initial 
rates of OATP1A2-mediated substrate uptake in HEK293 cells were linear over at least 
8 min, which was the time selected for subsequent experiments. The cells were then 
solubilized in 0.2 M NaOH, neutralized with 0.2 M HCl, and aliquoted for liquid 
scintillation counting. The uptake of [14C]-imatinib (final concentration 3 µM, 6.1 nCi/well) 
was undertaken in analogous fashion at 37oC in buffer contained 125 mM NaCl, 4.8 mM 
KCl, 5.6 mM D-glucose, 1.2 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4 and 25 mM 
HEPES (pH 5.0). The uptake of [3H] MTX (final concentration 5 µM, 94 nCi/well) was 
performed in PBS (pH 5.5; 25oC). Uptake was standardized to the amount of protein in 
each well. Kinetic studies were performed with varying concentrations of E3S (0.05-80 
µM) added to the uptake buffer for a 4 min incubation in cells and apparent Km and Vmax 
values for transporter activity were then calculated where possible (GraphPad Prism 
5.0; GraphPad Inc, LaJolla, CA, USA).  
Cell-surface biotinylation 
Cell-surface expression of OATP1A2 and variants was determined using the membrane 
impermeable biotinylation reagent NHS-SS-biotin (Quantum Scientific, Lane Cove West, 
NSW, Australia). Transporter cDNAs were expressed in HEK-293 cells in six-well plates 
using Lipofectamine 2000, as previously described (24). After 24 h, the medium was 
removed and the cells were washed with ice-cold PBS (pH 8.0; 3 mL). Cells were 
incubated on ice with 1 mL of freshly prepared NHS-SS-biotin (0.5 mg in PBS) for 30 
min with gentle shaking. After biotinylation, cells were washed with PBS containing 100 
mM glycine (3 mL) and then incubated on ice for 20 min to ensure complete quenching 
of the unreacted NHS-SS-biotin. The cells were then treated for 30 min with lysis buffer 
(10 mM Tris, 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-100, that contained 
the protease inhibitors phenylmethylsulfonyl fluoride, 200 mg/mL, and leupeptin, 3 
mg/mL, pH 7.4; 400 µL). Unlysed cells were removed by centrifugation at 14,000g at 
4°C. Streptavidin-agarose beads (50 µL; Quantum Scientific) were then added to the 
supernatant to isolate biotinylated cell membrane proteins. 
Electrophoresis and immunoblotting 
Protein samples were denatured, loaded onto 7.5% polyacrylamide minigels and 
electrophoresed using a mini cell (Bio-Rad, Gladesville, NSW, Australia). Proteins were 
transferred to polyvinylidene fluoride membranes in an electroelution cell (Bio-Rad) and 
blocked for 1 h with 5% nonfat dry milk in PBS-Tween (80 mM Na2HPO4, 20 mM 
KH2PO4, 100 mM NaCl, and 0.05% Tween 20, pH 7.5), washed, and then incubated 
overnight at 4°C with anti-OATP1A2 antibody (1 µg/mL; ThermoFisher Scientific, 
Scoresby, VIC, Australia; Cat. No: sc-48744). The membranes were washed, incubated 
with goat anti-rabbit IgG conjugated to horseradish peroxidase (1:5000; Sapphire 
Biosciences, Cat. No: sc-2004), and signals were detected using the Immobilon 
Western Chemiluminescent HRP Substrate (Merck Millipore, Kilsyth, 
VIC, Australia). 
Immunofluorescence of Transfected Cells 
Cells in which OATP1A2 and its variants were over-expressed were washed three times 
in PBS, fixed for 20 min at room temperature in 4% paraformaldehyde in PBS, and then 
rewashed in PBS. The fixed cells were permeabilized with 0.1% Triton X-100 for 10 min, 
incubated for 30 min at room temperature in PBS containing 5% goat serum and then 
incubated for 2 h in the same medium containing anti-OATP1A2 antibody (10 µg/mL). 
The cells were washed, and bound primary antibody was detected using Alexa Fluor® 
594 conjugate goat anti-rabbit IgG (Invitrogen Cat. No: A11012; 1:1000 dilution; 1 h). 
Treated cells were washed thoroughly, and the cover glasses were mounted in 
VECTASHIELD	   Mounting	   Medium	   (Abacus	   ALS, East	   Brisbane	   QLD, Australia). Samples were 
visualized with a Leica DMI3000 B epi fluorescence microscope (Leica Microsystems, 
North Ryde, NSW, Australia).  
 
Computer modeling 
3D structures of bacterial transporters were used in the present study as templates for 
modeling OATP1A2. In the most straightforward arrangement of the transporter 
structures, the 12 helices were arranged as a pair of distinct 6 helix bundles using the 
glycerol-3-phosphate transporter from E coli as template (GlpT, 1PW4) (25). 
Multiple sequence alignments were performed using CLUSTAL (26) as implemented in 
the European Bioinformatics Institute resource (27).  The sequence alignment retaining 
the transmembrane boundary predictions and template were used as inputs for the 
comparative protein modeling software MODELLER (28), using the graphical interface 
of Discovery Studio (v3.0, Accelrys, San Diego, CA, USA). The extended fifth 
extracellular loop between helices 9 and 10 (~105 amino acids) in the structure of 
OATP1A2 was least reliably modeled and was removed to prior to the analysis, along 
with the N- and C-termini that also do not align with the GlpT template. 
Statistics 
Data are presented throughout as mean±SEM. The Student’s t-test was used to test for 
differences between two sets of normally distributed data. Differences in transport 
function of OATP1A2 and multiple variants were detected by one-way analysis of 
variance and Dunnett's Testing. 
 
 
 
Results 
Identification of SLCO1A2 polymorphisms in a patient cohort 
Genomic DNA from twenty-two subjects was subjected to bidirectional resequencing of 
all coding exons of the SLCO1A2 gene (exons 3-16) using the primers detailed in Table 
1; exons 1 and 2 in SLCO1A2 are non-coding exons. In total, five nonsynonymous 
SNPs were identified in the patient cohort (allele frequencies and demographic factors 
are shown in Table 2). Two of the five novel SNPs in the SLCO1A2 gene (G763A and 
G862A in exon 9), that encoded the OATP1A2-V255I and OATP1A2-D288N variant 
transporters, respectively, were found in three heterozygous individuals. One individual 
was homozygous for the SNP A775C in exon 9 that encoded OATP1A2-T259P. The 
two remaining SNPs in SLCO1A2 were more widely distributed throughout the cohort. 
Thus, fourteen subjects were heterozygous for the G550A SNP in exon 7 that encoded 
OATP1A2-E184K (allele frequency 0.325) and nineteen were heterozygous for the 
G553A SNP in exon 7 (allele frequency 0.45) that encoded OATP1A2-D185N.  
Functional analysis of novel SLCO1A2 variants  
In human embryonic kidney (HEK-293) cells, the transient transfection of cDNA 
encoding wild-type OATP1A2 increased the influx of the reference substrate [3H]-E3S to 
~11-fold of control (Fig. 1A), while the influx of [3H]-MTX and [14C]-imatinib was 
increased to ~3.3-fold and ~2.0-fold of respective control (Fig. 1B, 1C). Under the test 
conditions basal rates of substrate uptake by wild-type OATP1A2 were 12.5 
pmol/(mg*min) for E3S, 57.5 pmol/(mg*min) for MTX and 53.8 pmol/(mg*min) for 
imatinib. 
In order to assess the impact of the novel SLCO1A2 variants on transporter function, 
HEK-293 cells were transfected with variant cDNAs that had been engineered by site-
directed mutagenesis. Transport of the model substrate E3S by the variants OATP1A2-
E184K, D185N, D288N and T259P was markedly altered compared to wild-type 
OATP1A2 (Fig. 1A). In the case of the OATP1A2-V255I variant transport function was 
slightly, but not significantly, decreased when E3S was the substrate. Compared to wild-
type, influx of the OATP1A2 substrate imatinib by the five novel OATP1A2 variants was 
also impaired (Fig. 1B). With the OATP1A2-E184K, -D185N, –T259P and –D288N 
variants the decrease in function was to ~40-50% of wild type control, while transport by 
OATP1A2-V255I was only slightly decreased (Fig. 1B). Similar trends were noted in 
MTX transport, with pronounced decreases observed for the variants, again with the 
exception of OATP1A2-V255I (Fig. 1C). 
Altered cellular expression of the novel variants of OATP1A2 
The mechanism underlying the decrease in the transport function of the novel 
OATP1A2 variants was assessed initially in transporter biotinylation and immunoblotting 
analyses in transfected HEK-293 cells. From densitometric analysis, the plasma 
membrane expression of the E184K, D185N, T259P and D288N variants was 
decreased markedly to ~20%-40% of wild type, whereas the expression of the V255I 
variant was unchanged (Fig. 1D). In confirmatory immunocolocalization experiments the 
expression of OATP1A2-E184K, D185N, T259N and D288N variants at the plasma 
membrane was decreased (Fig. 2). The specificity of biotinylation was confirmed by 
reprobing the immunoblotting membranes with an anti-actin antibody.  
Apart from impaired expression at the cell surface, transport function could also be 
decreased due to altered substrate affinity or turnover. Kinetic analysis of E3S transport 
was conducted in HEK-293 cells that expressed wild-type OATP1A2 and the D288N-
variant. Compared with wild-type the variant exhibited decreased apparent Km (12±1 
compared with 20±3 µM) and Vmax values (16.7±0.4 versus 36.7±1.8 pmol/µg protein*4 
min), which led to an approximate 25% decline in intrinsic clearance (Vmax/Km). Because 
the other novel OATP1A2 variants (E184K, D185N and T259P) had low transporter 
function conventional kinetic studies could not be conducted.  
Functional analysis of further mutants derived from the novel OATP1A2 variants 
Three of the four residues that were subject to naturally occurring polymorphisms in 
patient samples encoded acidic residues (E184, D185 and D288), while the fourth 
encoded the polar amino acid threonine (T259). Because the variant transporters all 
exhibited a loss-of-function we tested the hypothesis that these highly polar amino acids 
play important roles in OATP1A2 activity. We systematically mutagenized the residues 
to evaluate the impact on transport function of amino acid replacement. As shown in 
Figures 3A and 3B, function was retained providing acidic residues (aspartic or glutamic 
acids) were located at 184 and 185, because basic residues (lysine, arginine or 
histidine), or the neutral polar asparagine, encoded variants with greatly decreased 
activity (7%-63% of wild-type control). Interestingly, and in contrast with the findings with 
residues 184/185, either acidic or basic residues (glutamic acid, lysine, arginine or 
histidine) at position 288 supported full transporter function (Fig 3D), while neutral polar 
(asparagine or glutamine) or hydrophobic (valine) residues impaired E3S transport.  
The variant T259P, in which the neutral polar threonine residue is replaced by a rigid 
proline, also exhibited decreased function (to ~20% of wild-type control).  We further 
mutagenized the threonine to histidine (basic), or tyrosine, phenylalanine and 
tryptophan (neutral aromatic) residues that all have bulky side chains, or to alanine that 
has a small side chain. Transporter function was only impaired with variant amino acids 
that contained bulky side chains (3%-43% of wild-type control) because the transport 
capacity of OATP1A2-T259A was similar to wild-type (Fig 3C). In summary, these 
observations indicate that an acidic amino acid is essential at positions 184 and 185, 
while either acidic or basic residues at position 288 allows function to be retained. 
Inclusion of bulky amino acids in place of the polar threonine at position 259 markedly 
decreases function. 
To pursue potential mechanisms for the observed functional changes induced by 
replacement of the naturally occurring residues at these positions we investigated the 
expression of mutant transporters in whole cell lysates. From direct immunoblotting, 
signals corresponding to immunoreactive OATP1A2 protein were detected at ~65kD 
and ~90kD in lysates. Interestingly, because the total cell expression signal at ~90kD 
was decreased, particularly in the loss-of-function mutants engineered at residues 184, 
185 and 259 (Fig. 4A-C), but not those at residue 288 (Fig 4D), it appeared likely that 
the first three of these residues may play critical roles in maintaining the stability of the 
OATP1A2 protein.  
 
 Computational modeling of OATP1A2 
A crystal structure for OATP1A2 is not currently available but 3D structures of bacterial 
transporters have been reported and exhibit the basic topology proposed for human 
transporters (24, 25, 29, 30).   
To provide the most straightforward analysis, the 12 transmembrane domain helices in 
the arrangement, in which there were two separately identifiable 6 helix bundles, was 
considered suitable. The glycerol 3-phosphate transporter (GlpT) from E. coli (PDB ID 
1pw4) (25), which shares 8% sequence relatedness across the aligned regions, was 
selected as a suitable template (at 3.3 Å resolution). Model quality parameters 
determined by Molprobity were: rotamer outliers 7.1%, Ramachandran outliers 2.9%, 
Ramachandran favoured 91%, 34 Cβ deviations >0.25Å, residues with bad bonds 0.0%, 
and residues with bad angles 2.7% (31); this level of quality is suitable for the present 
purposes. As shown in Fig 5A, the residues E184 and D185 are within the second 
intracellular loop, while D288 is in the third intracellular loop and V255/T259 are in 
transmembrane helix six. Figs 5B and 5C show the putative conformation of OATP1A2 
and provide spatial context for the E184, D185 and D288 residues.  
 
 
 
 
 
 
 
 
Discussion 
OATP1A2 is a major transporter responsible for the cellular influx of important drugs 
such as imatinib, MTX, fexofenadine and HMG-CoA reductase inhibitors (3, 7, 10, 12, 
32-34). Pharmacogenetic variants of this transporter that have altered function may 
influence both the rate of drug influx and the toxicity of various agents in cells and in 
vivo (3, 9). The functional characterization and molecular evaluation of novel SLCO1A2 
genetic variants identified in patients could be significant for understanding inter-
individual variation in the response to drug substrates.  
The functional significance of five novel SLCO1A2 variants that were identified in a 
cohort of subjects was evaluated in vitro. Following transient transfection of the variant 
cDNAs into HEK-293 cells, transporter function and plasma membrane expression were 
determined. Variants that had decreased substrate transport activity also exhibited a 
corresponding decline in expression at the plasma membrane.  
One of the novel variants identified in the present study (SLCO1A2 G862A) encodes the 
variant residue D288N that is located within the large putative third intracellular loop 
between transmembrane domains 6 and 7. Three other SLCO1A2 variants that led to 
sequence changes in this loop have been identified previously (3). The truncated variant 
transporter OATP1A2-N278X was inactive, but neither OATP1A2-T277N nor I281V 
exhibited altered function with E3S or MTX (3). The present studies suggested that 
transporter function and membrane expression were decreased in the case of the 
D288N variant so that it is likely that this residue is important in membrane targeting. It 
is feasible that this residue may interact with an intracellular chaperone protein that 
directs OATP1A2 to the plasma membrane or that intramolecular interactions between 
residues stabilize the conformation of the transporter; the present investigation focused 
principally on the second possibility. From modeling considerations the location of D288 
may facilitate interactions with nearby basic residues in the large intracellular loop (such 
as K283, K289 or K291) or adjacent loops (such as K188 in intracellular loop 2 or K544 
in intracellular loop 5). It also emerged that replacement of D288 with basic amino acids 
retained E3S transport capacity and high plasma membrane expression. Again, a 
number of negatively charged residues, such as E285, E287, E292 and E293 are also 
in the vicinity of D288 and several others are present in adjacent loops. However, it is 
important to add that the large intracellular loop, and the large extracellular loop 
between transmembrane domains 9 and 10, are least reliably predicted by modeling 
and conformations other than that shown in Fig 5 are possible. 
Apart from OATP1A2-D288N, two other variants - OATP1A2-E184K and OATP1A2-
D185N - exhibited decreased cellular uptake of E3S, MTX and imatinib. The functional 
impairment in the cases of these two variants might be due to decreased cell surface 
and total cellular expression. From computer modeling, E184 and D185 were located 
within the second intracellular loop and could interact with adjacent positively charged 
residues, such as R85 in the first intracellular loop or K188, K295 and K296 in the 
second and third intracellular loops. Unlike the situation with D288, replacement of E184 
and D185 with basic amino acids led to loss of function. Presumably this could be due 
to a shortage of nearby negatively charged residues that might stabilize the 
conformation, or alternately that the region near 184/185 may have a pivotal role in the 
transport mechanism. Thus, it is feasible that the native OATP1A2 protein might be 
stabilized by specific ionic interactions and that replacement of important residues 
disrupts the interactions and destabilizes the protein. 
It has been suggested that transmembrane domain helices control membrane targeting, 
protein stability and substrate binding in SLC transporters (24, 35-37). In the case of 
residue T259, which is located in transmembrane domain 6, the present data suggest 
that the steric nature of the amino acid at this position is an important factor. While the 
residues threonine (polar amino acid) and alanine (small, hydrophobic amino acid) 
sustained transporter function and stability, the larger or more rigid histidine, tyrosine, 
phenylalanine, proline and tryptophan strongly disrupted transport function, perhaps by 
altering the conformation of the protein. 
Previous studies of the impact of pharmacogenetic variants of OATP1A2 on drug 
transport have yielded variable findings. Thus, imatinib uptake was decreased in cells 
containing the OATP1A2 variants *3 (E172D in transmembrane domain 4), *5 and *6 
(N128Y and N135I in intracellular loop 2), but not the *7 variant (T668S in the C-
terminal region) (23). Uptake of E3S and two peptide substrates was markedly impaired 
in the case of the *3 and *6 variants but less so with *5 and *7 (9). This resembled the 
present findings in relation to negatively charged intracellular residues in OATP1A2. 
Interestingly, similar findings have been noted with acidic intracellular residues in other 
SLC transporters. Thus, mutagenesis of acidic residues in the large intracellular loop in 
the human dipeptide transporter (hPEPT1; SLC15A1) and the E452K substitution in the 
C-terminus of the organic cation/carnitine transporter-2 (OCTN2; SLC22A5) also 
produced marked decreases in substrate transport (38, 39). It would now be of interest 
to evaluate in greater detail the incidence of pharmacogenetic variation in acidic 
residues in intracellular loops in human SLC transporters. 
 
Conclusion 
The tissue expression pattern of OATP1A2 is significant for tissue-specific drug 
disposition. Location in the distal tubules of nephrons, intestinal villi and endothelial cells 
that constitute the blood-brain barrier is clinically relevant, especially in view of the 
broad substrate specificity for this transporter. The present identification of novel 
variants of OATP1A2 that have impaired function and expression could affect the 
disposition of endogenous compounds and drugs in multiple tissues and contribute to 
inter-individual variability in drug responsiveness and toxicity. In this regard it is 
noteworthy that the very recent study by Angelini et al., reported that there were 
significant relationships between major and complete molecular responses in 189 
imatinib-treated patients with chronic myelogenous leukemia and the presence of 
pharmacogenetic variation in several SLC transporters, including OATP1A2 (40). 
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Table 1: Primers used in the sequencing of SLCO1A2 gene exons 
OATP1A2  Forward primer (5’-3’)  Reverse primer (5’-3’) 
Exon 3  GCGTTCCAGGTATTTTTG  GTTAGAAACCCTGCAAG  
Exon 4  CAATATTGAGGCTGCAACTG  GATGGAACCCTTAGTATCC  
Exon 5  CCCTCTGTAAATGTTGGTG  GACCTTTTTGTCAATGTAAGC 
Exon 6  GGTAGATCATCCACAGGCAG  CCTGGAGAGAGAACATATC 
Exon 7  CACTTACACTTGTCCATAC  TGTAGTGCCAAGCAGATG 
Exon 8  GTGACCCAGCATGAAAG  TAGAATTATCGGGTCCC 
Exon 9  GATAGACAGATAACCAGCC  ACCATAGGAAGAATCGG 
Exon 10  CCCAGTCAGCTACATCAC  GGTATTTCTGACCTCTTCC 
Exon 11  GTGGGTAATGTGTAACTAAG  CAAAGACAATCATGCACAC 
Exon 12  CTAACTGGGGATTGAGATGA CACTGGTCAGATGCTATGG  
Exon 13  GTTATATGGTGTAATCTTGAGAGA
C  GGAAGAAAAGTAGCGAGGAATAG  
Exon 14  CCCTGAATAACCAATAAGTGAGC  GACATTTGCTAGACTGCTTTTCTG 
Exon 15  GTTGCATTTGACCATAAGATTAC GAGAAGGCATTAGGAGAC 
Exon 16  GGATTTTCTCAGTGGGA AGCTGGCTCTAAGAATCT 
Table 2. Demographic factors in the subject cohort and novel nonsynonymous SNPs of 
SLCO1A2 identified in genomic DNA. 
 
Gender: 12M, 10F 
Age range: 38.3 – 68.8 yr 
Ethnic ancestry: Caucasian 16, Asian 3, Pacific Islander 2, Hispanic 1 
OATP1A2 
Variant 
Exon Nucleic 
Acid 
Position 
Allele Change Allele Frequency 
E184K 7 550 g=>a 0.325 
D185N 7 553 g=>a 0.450 
V255I 9 763 g=>a 0.075 
T259P 9 775 a=>c 0.050 
D288N 9 862 g=>a 0.075 
  
Figure Legends 
Fig 1. Transporter function and protein expression of OATP1A2 and its variants. A, B 
and C: Transport of 300 nM [3H] estrone sulphate (E3S), 3 µM [14C] imatinib and 5 µM 
[3H] methotrexate (MTX) in HEK-293 cells transfected with wild type and mutagenized 
variants of OATP1A2, relative to mock-transfected control (MOCK). Basal rates of 
substrate uptake by wild-type OATP1A2 were 12.5 pmol/(mg*min) for E3S, 57.5 
pmol/(mg*min) for MTX and 53.8 pmol/(mg*min) for imatinib. D: Western blot analysis of 
cell surface expression of wild-type OATP1A2 and its variant transporters. Upper panel: 
Cells were biotinylated, and the labeled cell surface proteins were precipitated with 
streptavidin beads and separated by gel electrophoresis, followed by Western blotting 
with anti-OATP1A2 antibody. Bottom panel: Densitometric analysis of transporter 
plasma expression. NC: negative control. Values are mean ± SE (n=3). Different from 
wild-type, * p<0.05; ** p<0.01.  
Fig 2. Immunofluorescence analysis of OATP1A2 and its variants expressed in HEK-
293 cells. Cells that over-expressed OATP1A2 and its variants were stained with anti-
OATP1A2 antibody and Alexa Fluor® 594 conjugate goat anti-rabbit IgG. Panels A ,C, 
E, G, I and K show the specific immunostaining of OATP1A2, which appears as bright 
fluorescence. Panels B, D, F, H, J, and L are phase-contrast images and show that cells 
remain fully attached to the culture dishes under the test conditions. WT: wild-type. 
Fig 3. Transporter function of the derivative mutants of OATP1A2. The transport of 300 
nM [3H] estrone sulphate (E3S) in HEK-293 cells transfected with wild type and 
derivative mutants of OATP1A2-E184 (A), -D185 (B), -T259 (C) and –D288 (D) (after 
subtraction of uptake in with mock-transfected control cells). Values are mean ± SE 
(n=3). Different from wild-type, * p<0.05; ** p<0.01;  
Fig 4. Protein expression of OATP1A2 and its mutants in HEK-293 cells. Western blot 
analysis of wild-type OATP1A2 and derivative mutants created at amino acid position 
184 (A), 185 (B), 259 (C) and 288 (D). Upper panels: Cell surface expression of 
OATP1A2 and its mutants. Cells were biotinylated, and the labeled cell surface proteins 
were precipitated with streptavidin beads and separated by gel electrophoresis, followed 
by Western blotting with anti-OATP1A2 antibody. Middle panels: Western analysis of 
total cellular expression of OATP1A2 and its mutants. Lower panels: after stripping, 
blots were reprobed with anti-actin antibody. WT: wild-type, NC: negative control. 
Fig 5.  Computer modeling of OATP1A2 structure. (A) The topological structure of 
OATP1A2 obtained by Transmembrane Helix Benchmarking software 
(www.sydney.edu.au/pharmacy/sbio/software/TMH_benchmark) based on the structure 
of GlpT and shown in the same orientation. Circled residues indicate the location of the 
amino acid replacements in the five novel variants found in the current study. The N- 
and C-termini are located intracellularly while a series of extracellular and intracellular 
loops connect the trans-membrane domains, (B) Proposed overall 3D structure showing 
transmembrane (TM) helices, extracellular (EC) and intracellular (IC) loops, and (C) a 
close up view, in the same orientation, of the intracellular region near the large loop 
showing the charged side chains. T259 is shown (orange) in TM6 of the helix bundle. 
Charged amino acids of the intracellular regions are colored blue and red for basic and 
acidic residues, respectively. The figures were drawn using PyMOL (DeLano Scientific; 
San Carlos, CA, USA). 
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